NASDAQ:TRVITrevi Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Trevi Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.40 +0.66 (+24.09 %) (As of 06/1/2020 04:00 PM ET) Add Compare Share Today's Range$2.68Now: $3.40▼$3.5950-Day Range$2.64MA: $2.76▼$2.9952-Week Range$1.33Now: $3.40▼$10.62Volume535,779 shsAverage Volume63,162 shsMarket Capitalization$60.64 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of nalbuphine ER to treat serious neurologically mediated conditions. The company's nalbuphine ER, which is in Phase IIb/III clinical trial is an oral extended release formulation of nalbuphine that is used for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinson's disease. Trevi Therapeutics, Inc. was founded in 2011 and is headquartered in New Haven, Connecticut.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingTrevi Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $16.75, Trevi Therapeutics has a potential upside of 392.6% from its current price of $3.40.Amount of Analyst CoverageTrevi Therapeutics has received no research coverage in the past 90 days. Previous Next 2.1 Community Rank Outperform VotesTrevi Therapeutics has received 43 “outperform” votes. (Add your “outperform” vote.)Underperform VotesTrevi Therapeutics has received 58 “underperform” votes. (Add your “underperform” vote.)Community SentimentTrevi Therapeutics has received 57.43% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Trevi Therapeutics and other stocks. Vote “Outperform” if you believe TRVI will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TRVI will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldTrevi Therapeutics does not currently pay a dividend.Dividend GrowthTrevi Therapeutics does not have a long track record of dividend growth. Previous Next 2.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Trevi Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,500.00 in company stock.Percentage Held by Insiders47.30% of the stock of Trevi Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions78.32% of the stock of Trevi Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Trevi Therapeutics are expected to grow in the coming year, from ($2.11) to ($2.10) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Trevi Therapeutics is -1.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Trevi Therapeutics is -1.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTrevi Therapeutics has a P/B Ratio of 1.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.65 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TRVI Previous Symbol CUSIPN/A CIKN/A Webwww.trevitherapeutics.com Phone203-304-2499Debt Debt-to-Equity RatioN/A Current Ratio7.47 Quick Ratio7.47Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.06 per share Price / Book1.11Profitability EPS (Most Recent Fiscal Year)($2.28) Net Income$-26,050,000.00 Net MarginsN/A Return on Equity-51.74% Return on Assets-46.55%Miscellaneous Employees15 Outstanding Shares17,835,000Market Cap$60.64 million Next Earnings Date8/10/2020 (Estimated) OptionableNot Optionable NASDAQ:TRVI Rates by TradingView Receive TRVI News and Ratings via Email Sign-up to receive the latest news and ratings for TRVI and its competitors with MarketBeat's FREE daily newsletter. Trevi Therapeutics (NASDAQ:TRVI) Frequently Asked Questions How has Trevi Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Trevi Therapeutics' stock was trading at $3.18 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, TRVI shares have increased by 6.9% and is now trading at $3.40. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Trevi Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Trevi Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Trevi Therapeutics. When is Trevi Therapeutics' next earnings date? Trevi Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 10th 2020. View our earnings forecast for Trevi Therapeutics. How were Trevi Therapeutics' earnings last quarter? Trevi Therapeutics Inc (NASDAQ:TRVI) issued its quarterly earnings data on Thursday, May, 7th. The company reported ($0.48) EPS for the quarter, missing the Zacks' consensus estimate of ($0.44) by $0.04. View Trevi Therapeutics' earnings history. What price target have analysts set for TRVI? 4 brokers have issued 1-year target prices for Trevi Therapeutics' stock. Their forecasts range from $14.00 to $20.00. On average, they anticipate Trevi Therapeutics' share price to reach $16.75 in the next year. This suggests a possible upside of 392.6% from the stock's current price. View analysts' price targets for Trevi Therapeutics. Has Trevi Therapeutics been receiving favorable news coverage? News articles about TRVI stock have been trending very positive recently, InfoTrie reports. The research firm identifies negative and positive press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Trevi Therapeutics earned a coverage optimism score of 3.5 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View the latest news aboutTrevi Therapeutics. Are investors shorting Trevi Therapeutics? Trevi Therapeutics saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 27,400 shares, an increase of 1,342.1% from the April 30th total of 1,900 shares. Based on an average trading volume of 71,700 shares, the short-interest ratio is presently 0.4 days. Currently, 1.1% of the company's shares are short sold. View Trevi Therapeutics' Current Options Chain. Who are some of Trevi Therapeutics' key competitors? Some companies that are related to Trevi Therapeutics include vTv Therapeutics (VTVT), Five Prime Therapeutics (FPRX), Chimerix (CMRX), Xeris Pharmaceuticals (XERS), Cerecor (CERC), Paratek Pharmaceuticals (PRTK), Avenue Therapeutics (ATXI), Tyme Technologies (TYME), Nature's Sunshine Products (NATR), Strongbridge Biopharma (SBBP), TAIWAN LIPOSOME/S (TLC), Kezar Life Sciences (KZR), Obseva (OBSV), NeuBase Therapeutics (NBSE) and Aytu Bioscience (AYTU). View all competitors. What other stocks do shareholders of Trevi Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Trevi Therapeutics investors own include Canopy Growth (CGC), AbbVie (ABBV), TapImmune (MRKR), AzurRx BioPharma (AZRX), Alibaba Group (BABA), Beyond Meat (BYND), Enterprise Products Partners (EPD), LYFT (LYFT), Mplx (MPLX) and Ovid Therapeutics (OVID). Who are Trevi Therapeutics' key executives? Trevi Therapeutics' management team includes the following people: Ms. Jennifer L. Good, Co-Founder, CEO, Pres & Director (Age 54)Mr. Thomas R. Sciascia, Co-Founder and Chief Medical Officer (Age 66)Mr. Christopher J. Seiter, Chief Financial Officer (Age 52)Dr. Helena Brett-Smith M.D., Chief Devel. Officer (Age 62)Dr. Amale Hawi, Sr. VP of CMC (Age 65) When did Trevi Therapeutics IPO? (TRVI) raised $70 million in an initial public offering on Tuesday, May 7th 2019. The company issued 4,700,000 shares at $14.00-$16.00 per share. SVB Leerink, Stifel and BMO Capital Markets served as the underwriters for the IPO and Needham & Company was co-manager. What is Trevi Therapeutics' stock symbol? Trevi Therapeutics trades on the NASDAQ under the ticker symbol "TRVI." Who are Trevi Therapeutics' major shareholders? Trevi Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Driehaus Capital Management LLC (0.66%). Company insiders that own Trevi Therapeutics stock include Anne Vanlent, Enterprise Associates 16 New, Invest A/S Lundbeckfond and Jennifer L Good. View institutional ownership trends for Trevi Therapeutics. Which major investors are selling Trevi Therapeutics stock? TRVI stock was sold by a variety of institutional investors in the last quarter, including Driehaus Capital Management LLC. View insider buying and selling activity for Trevi Therapeutics. How do I buy shares of Trevi Therapeutics? Shares of TRVI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Trevi Therapeutics' stock price today? One share of TRVI stock can currently be purchased for approximately $3.40. How big of a company is Trevi Therapeutics? Trevi Therapeutics has a market capitalization of $60.64 million. The company earns $-26,050,000.00 in net income (profit) each year or ($2.28) on an earnings per share basis. Trevi Therapeutics employs 15 workers across the globe. What is Trevi Therapeutics' official website? The official website for Trevi Therapeutics is www.trevitherapeutics.com. How can I contact Trevi Therapeutics? Trevi Therapeutics' mailing address is 195 CHURCH STREET 14TH FLOOR, NEW HAVEN CT, 06510. The company can be reached via phone at 203-304-2499 or via email at [email protected] This page was last updated on 6/2/2020 by MarketBeat.com Staff
